A Phase 3 interventional study of Osimertinib and Cisplatin in Non-Small Cell Lung Cancer, sponsored by AstraZeneca. Active, not recruiting at 158 sites in 25 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 43 under way, 8 of them phase 3. osimertinib · Carcinoma, Non-Small-Cell Lung.
Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, this one is the 9th largest by enrollment, is one of 8 that started in 2020, is one of 12 in phase 3, reaches primary completion later than 8 of the 42 other live ones, and was the 53rd registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →20 of the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung are open now, in 7 countries. Recruiting first, the newest first:
Maastricht University Medical Center · Sites in Netherlands
Ages 18+
AstraZeneca · Sites in China
Ages 18+
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–99
Shanghai Chest Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, osimertinib is the treatment under test here. Read study by study →
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 52 · Phase 3 12 · Phase 4 4
First in 2013; this study’s year is marked. 8 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 358 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 51 across the 90 interventional studies. Of the 32 that completed or were terminated, 21 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 90 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca: 25 open now, 78 under way, 28 of them phase 3. Of 123 finished, 45 (37%) have results posted.
Among the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 42nd largest by enrollment of the 137 interventional ones that give a count, is one of 11 that started in 2020, is one of 44 in phase 3, reaches primary completion later than 19 of the 77 other live ones, and was the 129th registered.
AstraZeneca’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
10 of the studies testing osimertinib in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05120349Phase 3AstraZenecaA Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection | 2027-08-02 |
| NCT04285671Jonsson Comprehensive Cancer CenterNecitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer | 2026-12-02 |
| NCT04322890Hunan Province Tumor HospitalTreatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation | 2026-12-24 |
| NCT07323641Jonsson Comprehensive Cancer CenterTelisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer | 2027-02-01 |
| NCT07485452Maastricht University Medical CenterBoosting Osimertinib Blood Brain Barrier Penetration | 2027-06 |
Add all 10 to your calendar (.ics) → With an account.
Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among AstraZeneca’s 209 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This is a Phase III, randomised, controlled, 3-arm, multi-centre study of neoadjuvant osimertinib as monotherapy or in combination with chemotherapy, versus SoC chemotherapy alone, for the treatment of patients with resectable EGFRm Non-Small Cell Lung Cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo plus investigator's choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin)
Drug: Cisplatin · Drug: Carboplatin · Drug: Placebo · Drug: Pemetrexed
Osimertinib 80 mg QD (Dose may be reduced to 40 mg QD at the discretion of the investigator) plus investigator's choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin)
Drug: Osimertinib · Drug: Cisplatin · Drug: Carboplatin · Drug: Pemetrexed
Osimertinib 80 mg QD (Dose may be reduced to 40 mg QD at the discretion of the investigator)
Drug: Osimertinib
Oral
Also known as: AZD9291; TAGRISSO
Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles.
Carboplatin (AUC5) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles
Oral
Pemetrexed (500 mg/m2) to be administered with cisplatin or carboplatin on Day 1 of every 3-week cycle for 3 cycles
Major Pathological Response (MPR) - IASLC Method
Defined as ≤10% viable cancer cells in the surgical specimen, as assessed per central pathology laboratory post-surgery (IASLC method). Patients will only be considered to have an MPR if they also have an R0 margin result.
Time frame: From date of randomization to an average of 12 weeks after the first dose
Major Pathological Response (MPR) - Chemotherapy Method
Defined as ≤10% viable cancer cells in the surgical specimen, as assessed per central pathology laboratory post-surgery (chemotherapy method). Patients will only be considered to have an MPR if they also have an R0 margin result.
Time frame: From date of randomization to an average of 12 weeks after the first dose
Pathological Complete Response (pCR) - IASLC Method
Defined as absence of any viable cancer cells in the dissected tumour samples, including the main tumour, lymph nodes, and margins as assessed per central pathology laboratory post-surgery using IASLC method. Patients will only be considered to have pCR if they also have an R0 margin result based on site assessment.
Time frame: From date of randomization to an average of 12 weeks after the first dose
Pathological Complete Response (pCR) - Chemotherapy Method
Defined as absence of any viable cancer cells in the dissected tumour samples, including the main tumour, lymph nodes, and margins as assessed per central pathology laboratory post-surgery using chemotherapy method. Patients will only be considered to have pCR if they also have an R0 margin result based on site assessment.
Time frame: From date of randomization to an average of 12 weeks after the first dose
Downstaging
Measured using pathologic mediastinal lymph node evaluation. Pathological downstaging is defined as baseline N2 patients becoming N1/N0 or N1 to N0 at the time of surgery. Only patients with pathological staging at both baseline and surgery are included in this analysis.
Time frame: From date of randomization to an average of 12 weeks after the first dose.
Concordance of EGFRm Status Between Tumor Tissue DNA and Patient-matched Plasma-derived ctDNA (Mutation Ex19Del or L858R)
Comparing the baseline central cobas® EGFR Mutation Test V2 between tumor tissue DNA and matched plasma ctDNA results (excluding invalid results). Since this endpoint uses pre-randomization data, treatment arms were combined for the analysis.
Time frame: Screening/Baseline
Concordance of EGFR Mutation Status Between the Local and Central Test Results From Baseline Tumor Samples (Mutation Ex19Del or L858R)
Comparing the local EGFR mutation test result used for patient selection with the retrospective baseline central cobas® EGFR Mutation Test V2 results (excluding invalid results). Since this endpoint uses pre-randomization data, treatment arms were combined for the analysis.
Time frame: Screening/Baseline
Change From Baseline in EORTC QLQ-C30 Primary Subscale Scores (Neoadjuvant Period)
Average change from baseline across all visits are reported. The analysis was performed using a MMRM analysis on the change from baseline in the score at each visit, including subject (random effect), treatment, visit (fixed effect \& repeated measure) and treatment by visit interaction as explanatory variables, with the baseline score as a covariate along with the baseline score by assessment interaction. EORTC QLQ-C30 has 30 questions and questions are combined to produce symptom scales, individual symptom items, functional scales, and global health status (GHS)/quality of life (QoL). Each of the scale/items range from 0-100 after a linear transformation. Positive change from baseline scores on the GHS/QoL and functioning scales indicate improvement on health status/function, and negative change scores on symptom scales/items represent less symptom severity/improvement on symptom status.
Time frame: Assessed at baseline, Cycle 2 Day1, Cycle 3 Day1, and Pre-surgical assessment (on D64, -1 to +21 days ).
Change From Baseline in EORTC QLQ-LC13 Primary Subscale Scores (Neoadjuvant Period)
Average change from baseline across all visits are reported. The analysis was performed using a MMRM analysis on the change from baseline in the score at each visit, including subject (as a random effect), treatment, visit (as fixed effect and repeated measure) and treatment by visit interaction as explanatory variables, with the baseline score as a covariate along with the baseline score by assessment interaction. EORTC QLQ-LC13 has 13 questions and scores range from 0-100 after a linear transformation. Questions assess cough, hemoptysis, dyspnea, site specific pain, sore mouth, dysphagia, peripheral neuropathy, and alopecia and pain medication. While the QLQ-LC13 includes more scales, only the Coughing, Pain in chest, and Dyspnea subscale scores were analyzed for this endpoint. Negative change from baseline scores indicates less symptom severity, and thus improvement on health status.
Time frame: Assessed at baseline, Cycle 2 Day1, Cycle 3 Day1, and Pre-surgical assessment (on D64, -1 to +21 days).
PK Plasma Concentrations of Osimertinib
Summary of plasma concentrations (nM) of Osimertinib
Time frame: From the pre-dose of Cycle 2 to post-dose of Cycle 3 (each cycle is 21 days)
PK Plasma Concentrations of AZ5104
Summary of plasma concentrations (nM) of AZ5104
Time frame: From the pre-dose of Cycle 2 to post-dose of Cycle 3 (each cycle is 21 days)
This Phase III, randomized, controlled, 3-arm, multi-center study was conducted in patients with resectable EGFRm NSCLC. A total of 1044 participants were screened between 16DEC2020 and 08DEC2023. 358 were randomized in a 1:1:1 ratio to 3 study arms. 2 participants were randomized to Osi + Chemo arm but did not receive any treatment (2 withdrawn).
| Milestone | Osimertinib + Chemo | Osimertinib | Placebo + Chemo |
|---|---|---|---|
| Started | 121 | 117 | 120 |
| Subject received any study treatment | 119 | 117 | 120 |
| Subjects ongoing neoadjuvant treatment | 0 | 0 | 0 |
| Subjects completed neoadjuvant treatment | 107 | 115 | 111 |
| Completed | 0 | 0 | 0 |
| Not completed | 121 | 117 | 120 |
| Withdrew: Death | 3 | 7 | 7 |
| Withdrew: Study ongoing | 115 | 109 | 110 |
| Withdrew: Withdrawal by subject | 2 | 1 | 3 |
| Withdrew: No reason is provided. | 1 | 0 | 0 |
Defined as ≤10% viable cancer cells in the surgical specimen, as assessed per central pathology laboratory post-surgery (IASLC method). Patients will only be considered to have an MPR if they also have an R0 margin result.
| Percentage of Participants | Osimertinib + Chemo | Osimertinib | Placebo + Chemo |
|---|---|---|---|
| Major Pathological Response (MPR) - IASLC Method | 25.6 (18.1 to 34.4) | 24.8 (17.3 to 33.6) | 1.7 (0.2 to 5.9) |
Defined as ≤10% viable cancer cells in the surgical specimen, as assessed per central pathology laboratory post-surgery (chemotherapy method). Patients will only be considered to have an MPR if they also have an R0 margin result.
| Percentage of Participants | Osimertinib + Chemo | Osimertinib | Placebo + Chemo |
|---|---|---|---|
| Major Pathological Response (MPR) - Chemotherapy Method | 24.8 (17.4 to 33.5) | 20.5 (13.6 to 29.0) | 1.7 (0.2 to 5.9) |
Defined as absence of any viable cancer cells in the dissected tumour samples, including the main tumour, lymph nodes, and margins as assessed per central pathology laboratory post-surgery using IASLC method. Patients will only be considered to have pCR if they also have an R0 margin result based on site assessment.
| Percentage of Participants | Osimertinib + Chemo | Osimertinib | Placebo + Chemo |
|---|---|---|---|
| Pathological Complete Response (pCR) - IASLC Method | 4.1 (1.4 to 9.4) | 8.5 (4.2 to 15.2) | 0 (0.0 to 3.0) |
Defined as absence of any viable cancer cells in the dissected tumour samples, including the main tumour, lymph nodes, and margins as assessed per central pathology laboratory post-surgery using chemotherapy method. Patients will only be considered to have pCR if they also have an R0 margin result based on site assessment.
| Percentage of Participants | Osimertinib + Chemo | Osimertinib | Placebo + Chemo |
|---|---|---|---|
| Pathological Complete Response (pCR) - Chemotherapy Method | 4.1 (1.4 to 9.4) | 8.5 (4.2 to 15.2) | 0 (0.0 to 3.0) |
Measured using pathologic mediastinal lymph node evaluation. Pathological downstaging is defined as baseline N2 patients becoming N1/N0 or N1 to N0 at the time of surgery. Only patients with pathological staging at both baseline and surgery are included in this analysis.
| Participants | Osimertinib + Chemo | Osimertinib | Placebo + Chemo |
|---|---|---|---|
| Baseline staging N1 or N2 | 50 | 48 | 29 |
| Baseline staging N1 | 25 | 28 | 22 |
| Baseline staging N2 | 25 | 20 | 7 |
Comparing the baseline central cobas® EGFR Mutation Test V2 between tumor tissue DNA and matched plasma ctDNA results (excluding invalid results). Since this endpoint uses pre-randomization data, treatment arms were combined for the analysis.
| Participants | Positive | Negative |
|---|---|---|
| Plasma ctDNA positive | 127 | 3 |
| Plasma ctDNA negative | 253 | 101 |
Comparing the local EGFR mutation test result used for patient selection with the retrospective baseline central cobas® EGFR Mutation Test V2 results (excluding invalid results). Since this endpoint uses pre-randomization data, treatment arms were combined for the analysis.
| Participants | Positive | Negative |
|---|---|---|
| Local results positive | 177 | 7 |
| Local results negative | 0 | 8 |
Average change from baseline across all visits are reported. The analysis was performed using a MMRM analysis on the change from baseline in the score at each visit, including subject (random effect), treatment, visit (fixed effect \& repeated measure) and treatment by visit interaction as explanatory variables, with the baseline score as a covariate along with the baseline score by assessment interaction. EORTC QLQ-C30 has 30 questions and questions are combined to produce symptom scales, individual symptom items, functional scales, and global health status (GHS)/quality of life (QoL). Each of the scale/items range from 0-100 after a linear transformation. Positive change from baseline scores on the GHS/QoL and functioning scales indicate improvement on health status/function, and negative change scores on symptom scales/items represent less symptom severity/improvement on symptom status.
| Score | Osimertinib + Chemo | Osimertinib | Placebo + Chemo |
|---|---|---|---|
| Functional Scale: Physical Functioning Score (Average change from Baseline) | -1.21 (-3.09 to 0.67) | 1.34 (-0.57 to 3.25) | -1.70 (-3.57 to 0.17) |
| Symptom Scale: Fatigue Score (Average change from Baseline) | 8.62 (5.81 to 11.42) | 2.64 (-0.21 to 5.49) | 5.95 (3.16 to 8.75) |
| Individual Symptom Item: Appetite Loss Score (Average change from Baseline) | 15.82 (12.35 to 19.29) | 9.44 (5.93 to 12.95) | 5.92 (2.47 to 9.38) |
| Global Health Status/ Quality of Life Score (Average change from Baseline) | -2.55 (-5.01 to -0.09) | -1.32 (-3.80 to 1.17) | -2.01 (-4.45 to 0.44) |
Average change from baseline across all visits are reported. The analysis was performed using a MMRM analysis on the change from baseline in the score at each visit, including subject (as a random effect), treatment, visit (as fixed effect and repeated measure) and treatment by visit interaction as explanatory variables, with the baseline score as a covariate along with the baseline score by assessment interaction. EORTC QLQ-LC13 has 13 questions and scores range from 0-100 after a linear transformation. Questions assess cough, hemoptysis, dyspnea, site specific pain, sore mouth, dysphagia, peripheral neuropathy, and alopecia and pain medication. While the QLQ-LC13 includes more scales, only the Coughing, Pain in chest, and Dyspnea subscale scores were analyzed for this endpoint. Negative change from baseline scores indicates less symptom severity, and thus improvement on health status.
| Score | Osimertinib + Chemo | Osimertinib | Placebo + Chemo |
|---|---|---|---|
| Coughing Score (Average change from Baseline) | -8.69 (-11.59 to -5.79) | -6.09 (-9.01 to -3.17) | -6.87 (-9.78 to -3.96) |
| Pain in Chest Score (Average change from Baseline) | 0.17 (-2.07 to 2.40) | -1.49 (-3.76 to 0.77) | 0.30 (-1.93 to 2.54) |
| Dyspnea Score (Average change from Baseline) | 1.16 (-0.87 to 3.18) | 0.73 (-1.31 to 2.78) | 0.84 (-1.19 to 2.87) |
Summary of plasma concentrations (nM) of Osimertinib
| nM | Osimertinib + Chemo | Osimertinib |
|---|---|---|
| Cycle2 Day1 - Predose | 333.1 ± 70.82 | 415.9 ± 55.7 |
| Cycle 2 Day 1 - Post-dose | 340.8 ± 74.11 | 406.6 ± 64.86 |
| Cycle 3 Day 1 - Predose | 300 ± 58.85 | 345.3 ± 47.63 |
| Cycle 3 Day 1 - Post-dose | 294.7 ± 62 | 357.3 ± 48.77 |
Summary of plasma concentrations (nM) of AZ5104
| nM | Osimertinib + Chemo | Osimertinib |
|---|---|---|
| Cycle2 Day1 - Predose | 45.08 ± 75.45 | 49.24 ± 68.01 |
| Cycle 2 Day 1 - Post-dose | 45.31 ± 73.56 | 48.46 ± 69.71 |
| Cycle 3 Day 1 - Predose | 40.52 ± 55.44 | 42.72 ± 47.87 |
| Cycle 3 Day 1 - Post-dose | 39.32 ± 58.47 | 42.86 ± 49.32 |
Collected over Includes adverse events during the neoadjuvant analysis period, defined as from the first dose to the minimum of (date of last dose in neoadjuvant period + 28 days, the next treatment start date - 1, date of withdrawal of consent, date of death). For participants who received Osimertinib or Placebo, this was up to 138 days. For participants who received Pemetrexed, Cisplatin or Carboplatin, this was up to 107 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Osimertinib + Chemo | 3/121 (2.5%) | 24/119 (20.2%) | 106/119 (89.1%) |
| Osimertinib | 7/117 (6%) | 13/117 (11.1%) | 88/117 (75.2%) |
| Placebo + Chemo | 7/120 (5.8%) | 24/120 (20%) | 101/120 (84.2%) |
| Event | Osimertinib + Chemo | Osimertinib | Placebo + Chemo |
|---|---|---|---|
| PneumoniaInfections and infestations | 2/119 | 3/117 | 4/120 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/119 | 2/117 | 0/120 |
| COVID-19Infections and infestations | 2/119 | 0/117 | 1/120 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 2/119 | 0/117 | 0/120 |
| EmbolismVascular disorders | 1/119 | 0/117 | 2/120 |
| ColitisGastrointestinal disorders | 0/119 | 0/117 | 2/120 |
| Wound infectionInfections and infestations | 0/119 | 1/117 | 0/120 |
| Coronary artery diseaseCardiac disorders | 0/119 | 1/117 | 0/120 |
| Diabetes mellitusMetabolism and nutrition disorders | 0/119 | 1/117 | 0/120 |
| HyponatraemiaMetabolism and nutrition disorders | 1/119 | 1/117 | 0/120 |
| Event | Osimertinib + Chemo | Osimertinib | Placebo + Chemo |
|---|---|---|---|
| ConstipationGastrointestinal disorders | 32/119 | 17/117 | 41/120 |
| NauseaGastrointestinal disorders | 33/119 | 8/117 | 29/120 |
| DiarrhoeaGastrointestinal disorders | 29/119 | 31/117 | 12/120 |
| Neutrophil count decreasedInvestigations | 30/119 | 2/117 | 22/120 |
| RashSkin and subcutaneous tissue disorders | 28/119 | 15/117 | 9/120 |
| Decreased appetiteMetabolism and nutrition disorders | 24/119 | 7/117 | 22/120 |
| Platelet count decreasedInvestigations | 23/119 | 5/117 | 3/120 |
| AnaemiaBlood and lymphatic system disorders | 22/119 | 6/117 | 22/120 |
| StomatitisGastrointestinal disorders | 22/119 | 10/117 | 12/120 |
| CoughRespiratory, thoracic and mediastinal disorders | 13/119 | 16/117 | 19/120 |
Full Analysis Set (All randomized participants, regardless of the treatment actually received)
| Age, Continuous(years) | Osimertinib + Chemo | Osimertinib | Placebo + Chemo | Total |
|---|---|---|---|---|
| Mean | 63.7 ± 9.83 | 64.8 ± 9.69 | 63.9 ± 9.66 | 64.1 ± 9.71 |
| Age, Customized(Participants) | Osimertinib + Chemo | Osimertinib | Placebo + Chemo | Total |
|---|---|---|---|---|
| <50 years | 11 | 10 | 11 | 32 |
| >=50 and <65 years | 51 | 41 | 48 | 140 |
| >=65 and <75 years | 41 | 49 | 48 | 138 |
| >=75 years | 18 | 17 | 13 | 48 |
| Sex: Female, Male(Participants) | Osimertinib + Chemo | Osimertinib | Placebo + Chemo | Total |
|---|---|---|---|---|
| Female | 72 | 76 | 90 | 238 |
| Male | 49 | 41 | 30 | 120 |
| Race/Ethnicity, Customized(Participants) | Osimertinib + Chemo | Osimertinib | Placebo + Chemo | Total |
|---|---|---|---|---|
| Asian | 87 | 88 | 90 | 265 |
| White | 29 | 27 | 29 | 85 |
| Other | 5 | 1 | 0 | 6 |
| Not reported | 0 | 1 | 1 | 2 |
| Race/Ethnicity, Customized(Participants) | Osimertinib + Chemo | Osimertinib | Placebo + Chemo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 7 | 6 | 8 | 21 |
| Not Hispanic or Latino | 114 | 111 | 111 | 336 |
| Not reported | 0 | 0 | 1 | 1 |
Showing the first 100 of 158 sites across 25 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Dec 2020 to primary completion in Oct 2024, 45 months.
Results were first posted in Jun 2026, 1 year 7 months after primary completion.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 45 months is above that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Osimertinib · Cisplatin · Carboplatin · Pemetrexed
Carcinoma, Non-Small-Cell Lung →